Publications by authors named "Stan B Kaye"

Claim this Profile
Q
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.
Michal M Hoppe, Patrick Jaynes, Joanna D Wardyn, Sai Srinivas Upadhyayula, Tuan Zea Tan, Stan B Kaye

EMBO Mol Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation.
Emily C Bartlett, Samuel V Kemp, Carole A Ridge, Sujal R Desai, Saeed Mirsadraee, Stan B Kaye

Lung Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
Robin L Jones, Mark J Ratain, Peter J O'Dwyer, Lillian L Siu, Jacek Jassem, Stan B Kaye

Eur J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services.
Cathryn A Moss, Elena Cojocaru, Janet Hanwell, Simon Ward, Wen Xu, Stan B Kaye

Eur J Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.
Raghav Sundar, Terri McVeigh, David Dolling, Ann Petruckevitch, Nikolaos Diamantis, Stan B Kaye

Eur J Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.
Terri Patricia McVeigh, Raghav Sundar, Nikolaos Diamantis, Stan B Kaye, Udai Banerji

Eur J Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.
Raquel Perez-Lopez, Desam Roda, Begona Jimenez, Jessica Brown, Joaquin Mateo, Stan B Kaye

Oncotarget· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
Marta Capelan, Desamparados Roda, Elena Geuna, Karim Rihawi, Shankar Bodla, Stan B Kaye

Lung Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Saeed Rafii, Charlie Gourley, Rajiv Kumar, Elena Geuna, Joo Ern Ang, Stan B Kaye

Oncotarget· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
Angela George, Rebecca Kristeleit, Saeed Rafii, Caroline O Michie, Rebecca Bowen, Stan B Kaye

Eur J Cancer· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Bradley J Monk, Domenica Lorusso, Antoine Italiano, Stan B Kaye, Miguel Aracil

Cancer Treat Rev· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.
Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, Yasmin J Asad, Alan T Henley, Stan B Kaye

Mol Cancer Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.
Joaquin Mateo, David Olmos, Herlinde Dumez, Srinivasu Poondru, Nancy L Samberg, Stan B Kaye

Br J Cancer· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP inhibitors: the race is on.
Jessica S Brown, Stan B Kaye, Timothy A Yap

Br J Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, Timothy J Perren, Gordon C Jayson, Stan B Kaye

Lancet· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases.
Owen Mortimer Heath, Heleen J van Beekhuizen, Vivek Nama, Desiree Kolomainen, Marielle A E Nobbenhuis, Stan B Kaye

Thromb Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
Robin L Jones, Edward S Kim, Pilar Nava-Parada, Salma Alam, Faye M Johnson, Stan B Kaye

Clin Cancer Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Debashis Sarker, Joo Ern Ang, Richard Baird, Rebecca Kristeleit, Krunal Shah, Stan B Kaye

Clin Cancer Res· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.
Victor Moreno García, David Olmos, Carlos Gomez-Roca, Philippe A Cassier, Rafael Morales-Barrera, Stan B Kaye

Clin Cancer Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit.
Khurum Khan, Joo Ern Ang, Naureen Starling, Francesco Sclafani, Krunal Shah, Stan B Kaye

Gastric Cancer· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Sophie Postel-Vinay, Laurence Collette, Xavier Paoletti, Elisa Rizzo, Christophe Massard, Stan B Kaye

Eur J Cancer· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.
Xavier Paoletti, Christophe Le Tourneau, Jaap Verweij, Lillian L Siu, Lesley Seymour, Stan B Kaye

Eur J Cancer· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
Joo Ern Ang, Charlie Gourley, C Bethan Powell, Hilda High, Ronnie Shapira-Frommer, Stan B Kaye

Clin Cancer Res· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Shahneen K Sandhu, William R Schelman, George Wilding, Victor Moreno, Richard D Baird, Stan B Kaye

Lancet Oncol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.
Emma Kipps, David S P Tan, Stan B Kaye

Nat Rev Cancer· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis